CorMedix Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CorMedix Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $311.71M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $43.47M | Mar 5, 2026 |
| FY2023 | Dec 31, 2022 | $65.4K | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $190.9K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $239.2K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $283.3K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $429.8K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $329.3K | May 29, 2019 |
| FY2016 | Dec 31, 2016 | $121 | Mar 16, 2017 |
| FY2016 | Sep 30, 2016 | $44 | Mar 16, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $275.75M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $40.28M | Mar 5, 2026 |
| FY2023 | Dec 31, 2022 | $61.7K | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $42.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $34.4K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($90.0K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $33.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $214.4K | May 29, 2019 |
| FY2016 | Dec 31, 2016 | $36 | Mar 16, 2017 |
| FY2016 | Sep 30, 2016 | $0 | Mar 16, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $163.06M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($17.93M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($46.34M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($29.70M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($28.21M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($22.03M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($16.43M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($26.83M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($33.01M) | May 29, 2019 |
| FY2016 | Dec 31, 2016 | ($6.4K) | Mar 16, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.14M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($22.36M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($48.96M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($30.62M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($29.44M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($27.22M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($21.01M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($26.86M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($32.92M) | May 29, 2019 |
| FY2016 | Dec 31, 2016 | ($6.4K) | Mar 16, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.33M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.94M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $13.16M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $10.68M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $13.13M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $13.38M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $11.05M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $18.82M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $24.49M | May 29, 2019 |
| FY2016 | Dec 31, 2016 | $4.0K | Mar 16, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $35.80M | Mar 12, 2024 |
| FY2023 | Dec 31, 2022 | $20.01M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $16.35M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $13.88M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $9.87M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $8.07M | Mar 16, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $175.05M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($50.62M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($38.41M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($24.36M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($21.16M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($21.97M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($15.05M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($23.70M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($28.59M) | May 29, 2019 |
| FY2017 | Dec 31, 2016 | ($22.27M) | Mar 19, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $116.0K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $327.3K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $219.4K | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $1.43M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $112.6K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $36.6K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $48.9K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $152.0K | May 29, 2019 |
| FY2017 | Dec 31, 2016 | $58.7K | Mar 19, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $826.14M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $118.85M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $82.06M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $62.04M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $68.95M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $49.31M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $29.48M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $18.83M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $13.45M | May 29, 2019 |
| FY2017 | Dec 31, 2016 | $21.91M | Mar 19, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $420.84M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $34.19M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $11.92M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $6.98M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $6.15M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.09M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.83M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $13.89M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $6.26M | May 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.09M | Mar 19, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $405.31M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $84.66M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $70.14M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $55.06M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $62.80M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $44.22M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $23.65M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $4.93M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $7.19M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $17.81M | May 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.00M | Mar 5, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($176.58M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($339.63M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($321.70M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($275.36M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($245.66M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($217.45M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($195.42M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($178.99M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($152.17M) | May 29, 2019 |
| FY2017 | Dec 31, 2016 | ($119.16M) | Mar 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $144.84M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $40.65M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $43.64M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $43.15M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $53.32M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $41.91M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $16.35M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $17.62M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $10.38M | May 29, 2019 |
| FY2017 | Dec 31, 2016 | $8.06M | Mar 19, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 79.26M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 64.41M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 54.94M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 42.82M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 38.09M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 33.56M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 25.67M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 21.78M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 71.41M | May 29, 2019 |
| FY2017 | Dec 31, 2016 | 40.43M | Mar 19, 2018 |